Gastroenterology

Dicerna, Novo Nordisk partner to develop novel liver disease therapies

Dicerna Pharmaceuticals and Novo Nordisk announced an agreement to develop RNA interference therapies for liver-related cardiometabolic diseases, according to a press release.
“We are excited to collaborate with Novo Nordisk on this broad research and development effort that extends the reach of our GalXC platform to a wide range of liver cell targets and maximizes our opportunities in serious liver diseases,” Douglas M. Fambrough, PhD, president and CEO of Dicerna, said in the release.
As part of the agreement, Novo Nordisk will have access to Dicerna’s proprietary GalXC RNAi

Source link

Related posts

High-fat diet linked to unfavorable gut microbiota changes

Newsemia

New pathways in development of liver cancer

Newsemia

The Global Paradigm Shift in Screening for Colorectal Cancer

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World